Isoproterenol hydrochloride injection is indicated to improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output and for treatment of bronchospasm occurring during anaesthesia. The said drug is equivalent to reference listed drug (RLD), Isuprel Injection.

The pharma company said that the drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara.

According to IQVIA MAT February 2023 data, Isoproterenol Hydrochloride Injection USP, 0.2 mg/mL and 1 mg/5 mL (0.2 mg/mL) had annual sales of $28.5 million in the United States.

As of 31 December 2022, the group now has 362 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company's consolidated net profit jumped 24.5% to Rs 622.90 crore on 17.9% rise in net sales to Rs 4,159.80 crore in Q3 FY23 over Q3 FY22.

Shares of Zydus Lifesciences rose 0.44% to Rs 505.85 on the BSE.